Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Intraocular Lymphoma × zanubrutinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 20 Leukemia, Lymphocytic, Chronic, B-Cell 16 Lymphoma, Mantle-Cell 14 Lymphoma, Follicular 9 Waldenstrom Macroglobulinemia 8 Lymphoma, B-Cell, Marginal Zone 5 Lymphoma, B-Cell 5 Lymphoma 5 Recurrence 4 Lymphoma, Non-Hodgkin 3 Neoplasms 1 Multiple Myeloma 1 Lymphohistiocytosis, Hemophagocytic 1 Leukemia, B-Cell 1 Leukemia 1 Intraocular Lymphoma 1 Dendritic Cell Sarcoma, Interdigitating 1 Cardiovascular Diseases 1

Interventions

Rituximab 14 Peripheral Blood Stem Cell Transplantation 12 Cyclophosphamide 12 fludarabine phosphate 10 Whole-Body Irradiation 9 Mycophenolic Acid 7 Filgrastim 7 Methotrexate 6 Lenalidomide 6 Etoposide 6 Cyclosporine 6 Radiotherapy 5 Dexamethasone 5 Cytarabine 5 Tacrolimus 4 Carboplatin 4 Thiotepa 3 Therapeutics 3 Melphalan 3 Granulocyte Colony-Stimulating Factor 3 Flow Cytometry 3 Busulfan 3 Antilymphocyte Serum 3 pegfilgrastim 2 etoposide phosphate 2 Transplantation 2 Psychiatric Rehabilitation 2 Polymerase Chain Reaction 2 Pentetic Acid 2 Indium 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06973811 2025-05-20

ZR-MTX

Peking Union Medical College Hospital

Phase 2 Not yet recruiting

Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡